公开(公告)号：US11179365B2

公开(公告)日：2021-11-23

申请号：US16190298

申请日：2018-11-14

Applicant: NOVARTIS AG

Inventor： Tinya Abrams ,  Larry Alexander Gaither

IPC: A61K31/381 ,  A61K31/519 ,  A61P35/00 ,  A61K9/00

Abstract: The present invention relates to a pharmaceutical combination comprising LSZ102 and ribociclib; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of conditions in which degradation of estrogen receptors combined with CDK4/6 inhibition is beneficial in, for example, the treatment of cancers.

公开(公告)号：US20210000810A1

公开(公告)日：2021-01-07

申请号：US16869450

申请日：2020-05-07

Applicant: NOVARTIS AG

Inventor： Tinya Abrams ,  Larry Alexander Gaither

IPC: A61K31/4439 ,  A61P35/00 ,  A61K31/381

Abstract: The present invention relates to a pharmaceutical combination comprising LSZ102 and alpelisib; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of conditions in which degradation of estrogen receptors combined with PI3K inhibition is beneficial in, for example, the treatment of cancers.

公开(公告)号：US10695333B2

公开(公告)日：2020-06-30

申请号：US16204471

申请日：2018-11-29

Applicant: NOVARTIS AG

Inventor： Tinya Abrams ,  Larry Alexander Gaither

IPC: A61K31/4439 ,  A61P35/00 ,  A61K31/381 ,  C07D409/06

Abstract: The present invention relates to a pharmaceutical combination comprising LSZ102 and alpelisib; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of conditions in which degradation of estrogen receptors combined with PI3K inhibition is beneficial in, for example, the treatment of cancers.

公开(公告)号：US20130323252A1

公开(公告)日：2013-12-05

申请号：US13690269

申请日：2012-11-30

Applicant: NOVARTIS AG

Inventor： Larry Alexander Gaither ,  Christopher John Rothwell

IPC: C07K16/30

CPC classification number: C07K16/30 ,  C07K16/28 ,  C07K2317/34 ,  C07K2317/77

Abstract: The present invention provides molecules that bind to TMEM16A (“TMEM16A binding molecules”), particularly human or humanized antibodies and antibody drug conjugates that bind to human TMEM16A and modulate its functions. Epitopes of TMEM16A and molecules that bind these epitopes are also provided herein.

Abstract translation: 本发明提供结合TMEM16A（“TMEM16A结合分子”）的分子，特别是结合人TMEM16A并调节其功能的人或人源化抗体和抗体药物偶联物。 TMEM16A的表位和结合这些表位的分子也在本文中提供。